Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

BACKGROUND: Selective kinase and immune checkpoint inhibitors, and their combinations, have significantly improved the survival of patients with advanced metastatic melanoma. Not all patients will respond to treatment however, and some patients will present with significant toxicities. Hence, the id...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Su Yin, Lee, Jenny H., Welsh, Sarah J., Ahn, Seong Beom, Breen, Edmond, Khan, Alamgir, Carlino, Matteo S., Menzies, Alexander M., Kefford, Richard F., Scolyer, Richard A., Long, Georgina V., Rizos, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681837/
https://www.ncbi.nlm.nih.gov/pubmed/29152306
http://dx.doi.org/10.1186/s40364-017-0112-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681837/
https://www.ncbi.nlm.nih.gov/pubmed/29152306
http://dx.doi.org/10.1186/s40364-017-0112-9

Ejemplares similares